Cargando…
Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
PURPOSE: This single-arm, open-label study aimed to explore the effects of extended-release paliperidone on social and cognitive function in patients with schizophrenia. METHODS: Paliperidone extended-release (flexible dose ranging from 3 to 12 mg/day orally) was administered for 24 weeks in patient...
Autores principales: | Shi, Chuan, Yao, Shu Qiao, Xu, Yi Feng, Shi, Jian Guo, Xu, Xiu Feng, Zhang, Cong Pei, Jin, Hua, Yu, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006669/ https://www.ncbi.nlm.nih.gov/pubmed/27601904 http://dx.doi.org/10.2147/NDT.S112542 |
Ejemplares similares
-
Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang, Hongyan, et al.
Publicado: (2016) -
Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
por: Chen, Ching-Yen, et al.
Publicado: (2018) -
Effects of paliperidone extended release on the symptoms and functioning of schizophrenia
por: Huang, Min-Wei, et al.
Publicado: (2012) -
Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang, Fu De, et al.
Publicado: (2017) -
Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study()
por: Pandina, Gahan, et al.
Publicado: (2020)